\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes HealthThe Global Health EDCTP3 Joint Undertaking has published its Work Programme 2026, announcing €147 million to fund research and innovation projects tackling major global health challenges.
The 2026 calls for proposals will open mid-January 2026 and include six topics:
four research and innovation action (RIA) topics (two-stage) aimed at developing new or improved TB drugs, supporting the prevention and management of lower respiratory tract infections, ensuring better prevention, treatment and management of HIV and its co-infections and co-morbidities, and addressing the global challenge of climate and health. Deadline for short proposals is 4 March 2026 (first stage). Succesful consortia at the first stage will be invited to submit a full proposal by 17 September 2026 (second stage).
two coordination and support action (CSA) call topics (single-stage) will support training and capacity-building activities in the areas of ethics, regulatory and pharmacovigilance, and enhance integrated research and healthcare through digital innovation and artificial intelligence. Deadline for submission is 31 August 2026.
More information on the Global Health EDCTP3 website. An online Info Day will take place on 5 February 2026.
The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association whose members are several EU Member States and Associated countries and several African countries.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The European Cybersecurity Competence Centre (ECCC) has opened a call for tenders to set up a European testing infrastructure for post-quantum cryptography (PQC). Open to applicants across the European Economic Area, the contract is worth EUR 25 million and covers IT services including development and support. The submission deadline is 20 Februa... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
